Member Info for krafty1305

Definitely a mention of multi variant vaccines under development and their importance . Anyone else doing one apart from us.

Is that 97.5% less effective?

Just read apparently Pfizer is 40% less effective against Omnicron. I would assume that is a significant piece of data Not really a better place to test Covidity than South Africa.

a small positive reaction from last night rather than the falls after one of Cliff's presentations. In our leader we trust.

Lindy should actually be in the room considering the subject matter. If not at least Jonathan Ball

1. Omicron is spreading rapidly in South Africa and it is seeded across the world much of which is unvaccinated still
2. Mutations of the S protein are a continual risk with a global travelling world and trade . Short of curtailing global trade and travel this can not be stopped.
3. It takes 100 days to adapt first generation vaccines let alone jab 7 billion people so with first generation vaccines we will always be being the curve
4. Boosters every 3 to 6 months seem to be required for first generation vaccines again for 7 billion people which is very expensive and logistically impossible.

So I would suggest a vaccine which does not have to be adapted and has longer lasting effects would be of great interest to Cepi, the WHO and all governments. By April we will know the final piece of the jigsaw regarding the effectiveness of Covidity and how effective it is after 6 months and how many people have caught Covid using Covidity well before that within say 3 months. Finally we are ahead of the curve because of product is formulated and on trial and within a Covid hotspot.

PS. Wouldn't it be great if first jab of Moditope could be given too!

Surely the appearance of a new high profile variant where it is particularly prevalent where the trial is taking place is surely a good thing. Neutralising the core N protein negating the need to continuously tweak the vaccine is what we are trying to prove plus if the vaccine is still strong after 6 months rather than needing a top up every 6 months is the other point then obviously we need to wait until April to prove that point. The first point will be shown quicker than the second.We now know that the S protein will continuously mutate and the present vaccines are not probably up to the job mutation wise as it takes 100 days to tweak it and the longer to manufacture. We also know top up boosters are required for 7 billion people every 6 months.So in my mind we are ahead of the curve now and if the trial succeeds in proving both points we will all be very well off. Finally I feel the government is well aware of what we are doing but they need everyone to use what we have now to get us through winter now rather than talk about what we might be able to have next winter.

So what do we know this morning.
1. Moderna CEO saying efficacy against new variant no as good so futures down as Roses points out.
2 Confirmed that even though vaccines can be tweaked, takes 100 days for that to happen so chasing the S protein is not a long term solution
3. Until the world is vaccinated this will carry on ad-finitum.
4. Seems vaccines is the only way out and with our knowledge we know targeting and beating the more stable N protein is the only long term practical solution.
5. Several weeks in to our trial and no bad news reported which is a major thing for me.
6. Once our results are out, due to the fact Covid is the number 1 issue right now, this will become a traders dream and Hasiba will be a happy bunny

surely it will be tested by default

Kashdog. You are the missing the whole point of Covidity. The spike protein is infinitely variable so vaccines which only target S protein need to be changed all the time like the flu vaccine. What Lindy is by using our patented immunobody technology is vaccine against the core non changing "N' protein which does not change hence its universality for want of a better word. That is my simplistic understanding and whew might have the jackpot with Covidity never mind all our core cancer vaccines

£1bn is only £1.25 a share so as dramatic as that statement sounds its actually quite cautious if you think about it for solving multiple forms of cancer and covid. Novavax is worth over $10bn and Biontech over £50bn. Just saying

as i said we are outside the top 20.

why make it political on here. UK not in top 20 in Europe for deaths per million or top 30 for the world and with our booster programme now at almost 500,000 a day our figures should calm down. Happy to say its a failure of the western world and discuss that but to point finger at us especially considering how densely populated we are is unhelpful

i read 30% survival rates for 5 years as opposed to our over 80% for original small trial

from Merck's latest results.
"Second-Quarter 2021 Worldwide Sales from Continuing Operations (Excluding Organon) Were $11.4 Billion, 22% Above Second-Quarter 2020; Excluding the Impact from Foreign Exchange, Sales Grew 19% Reflecting Ongoing Recovery from the COVID-19 Pandemic and Strong Underlying Demand Across the Company’s Portfolio of Innovative Products:
KEYTRUDA Sales Grew 23% to $4.2 Billion; Excluding the Impact from Foreign Exchange, Sales Grew 20%"

yes $4.2bn for keytuda alone in one quarter on a drug which is patchy at best on results and side effects. If SC1B1 improves that significantly, Merck will do the deal I suggest and then you do the maths

Hasiba financial deals and partnerships are done on phase 2 data. If SC1B1 improves the performance of Keytruda significantly ie doubling the success rate, a deal could not be done. of course it can Sales are forecast to be in billions with only 30% success rate. so phase 2 data drives the deal which of course will drive the share price. Most logical outcome if current trial is successful against required benchmarks as we can not afford phase3 anyway.

out time will come. Covid cases rising exponentially again. Even though it is the unvaccinated driving this I would assume a new variant will crop up which may evade the current vaccine programme. As we know so many are refusing vaccine in many western countries Covid not going anywhere soon and at least in those willing to be vaccinated ours will be a magnificent thing

Interestingly small amounts of money and pre clinical. Not what we we are looking for

to be honest more interested in Johnny's post below and Covidity passing its first test. Novavax went up from $5 at base (so say 5p for us) up to $300 a share on announcement of Cepi deal for its covid vaccine, Though it has slipped back still worth nearly $13bn. So a slither of hope means I don't worry about short term movements and am more intrigued to every box being ticked regarding infrastructure and trial progress. Any disasters we would have heard about, so so far so good. With Moditope and the other platforms still bubbling away nicely to add to this, just impatiently waiting like everyone else. With over 500,000 shares accumulated in my ISA, can't find anything else with the potential upside we have here. Novavax chart is below if you want to have a look
https://www.hl.co.uk/shares/shares-search-results/n/novavax-inc-usd0.01

looks like by this time next year, there will be half a dozen trials live. that is pretty impressive. if only 2 come off, this will be in the £s. No one can now say there is not a plan and plenty of money to take it reasonably far down the road. Laid out in black and white